NDATOPICALLOTION
Approved
May 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
NIX (permethrin) by Design Pharmaceuticals is clinical pharmacology permethrin, a pyrethroid, is active against a broad range of pests including lice, ticks, fleas, mites, and other arthropods. First approved in 1990.
Drug data last refreshed 9h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIX (permethrin) is a topical pyrethroid insecticide approved in 1990 for treating scabies and head lice (pediculosis capitis). It works by disrupting sodium channel currents in pest nerve cell membranes, causing paralysis and death of arthropods. The drug is rapidly metabolized to inactive metabolites and exhibits minimal systemic absorption (<2% of applied dose).
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling shrinking team resources and transition focus to generic defense or lifecycle extensions.
Mechanism of Action
CLINICAL PHARMACOLOGY Permethrin, a pyrethroid, is active against a broad range of pests including lice, ticks, fleas, mites, and other arthropods. It acts on the nerve cell membrane to disrupt the sodium channel current by which the polarization of the membrane is regulated. Delayed repolarization…
Pharmacologic Class:
Pyrethroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Natrunix in HLA-B27 Positive Subjects With Axial Spondyloarthritis
Started Aug 2026
60 enrolled
Axial Spondyloarthritis
Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment
Started Jul 2026
108 enrolled
Rheumatoid Arthritis
Project PHOENIX: Molecular Signatures of Burn Pit Exposure
Started May 2026
1,000 enrolled
Burn Pit ExposureAirborne Hazard ExposureVeteran Health+4 more
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
Started Jan 2026
61 enrolled
Lung Adenocarcinoma
Augmented Reality BCI Longitudinal Study for Persons With ALS, Stroke, TBI and SCI Utilizing Cognixion + Apple Vision Pro
Started Oct 2025
10 enrolled
ALS (Amyotrophic Lateral Sclerosis)TBI Traumatic Brain InjurySCI - Spinal Cord Injury+1 more
Worked on NIX at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.